SIRs for tAML overall and by latency after initial chemotherapy treatment of first primary malignancy in adulthood, 9 SEER registries, 1975-2008
| First primary malignancy . | . | . | . | . | By latency . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall . | 1.0-4.9 y . | 5.0-9.9 y . | ≥10.0 y . | ||||||||||
| N . | EAR/10 000* . | SIR* . | (95% CI) . | N . | SIR* . | (95% CI) . | N . | SIR* . | (95% CI) . | N . | SIR* . | (95% CI) . | |
| Total† | 801 | 3.04 | 4.70‡ | (4.38-5.04) | 487 | 6.07‡ | (5.54-6.64) | 223 | 4.62‡ | (4.03-5.26) | 91 | 2.17‡ | (1.74-2.66) |
| Buccal cavity, pharynx | 5 | 0.58 | 1.67 | (0.54-3.90) | 4 | 2.37 | (0.64-6.06) | <3 | 1.22 | (0.03-6.77) | 0 | § | (0.00-7.69) |
| Esophagus | 6 | 3.65 | 3.84‡ | (1.41-8.36) | 4 | 3.87‡ | (1.06-9.92) | <3 | 2.66 | (0.07-14.81) | <3 | 6.55 | (0.17-36.52) |
| Stomach | 5 | 1.56 | 2.36 | (0.77-5.50) | 3 | 2.43 | (0.50-7.11) | <3 | 4.33 | (0.52-15.66) | 0 | § | (0.00-8.64) |
| Colon | 25 | 0.2 | 1.16 | (0.75-1.71) | 11 | 1.06 | (0.53-1.89) | 7 | 1.07 | (0.43-2.20) | 7 | 1.50 | (0.60-3.10) |
| Rectum, rectosigmoid junction | 15 | 0.25 | 1.20 | (0.67-1.98) | 7 | 1.11 | (0.45-2.29) | 4 | 1.05 | (0.29-2.68) | 4 | 1.68 | (0.46-4.31) |
| Anus, anal canal, anorectum | 6 | 2.21 | 3.24‡ | (1.19-7.04) | 3 | 3.70 | (0.76-10.80) | <3 | 3.43 | (0.42-12.39) | <3 | 2.18 | (0.06-12.12) |
| Biliary tract | 4 | 4.58 | 5.52‡ | (1.50-14.13) | 3 | 5.77‡ | (1.19-16.86) | <3 | 7.59 | (0.19-42.29) | 0 | § | (0.00-50.48) |
| Larynx | 3 | 2.14 | 3.02 | (0.62-8.81) | 0 | § | (0.00-6.54) | 3 | 10.33‡ | (2.13-30.19) | 0 | § | (0.00-26.26) |
| Lung, bronchus | 65 | 6.49 | 6.82‡ | (5.26-8.69) | 54 | 7.96‡ | (5.98-10.39) | 9 | 4.70‡ | (2.15-8.91) | <3 | 2.38 | (0.29-8.61) |
| Small-cell | 32 | 11.13 | 11.04‡ | (7.55-15.58) | 27 | 14.28‡ | (9.41-20.78) | 3 | 4.51 | (0.93-13.17) | <3 | 5.84 | (0.71-21.09) |
| Non–small-cell | 32 | 4.35 | 4.87‡ | (3.33-6.88) | 26 | 5.37‡ | (3.51-7.87) | 6 | 4.84‡ | (1.78-10.54) | 0 | § | (0.00-7.55) |
| Bones and joints | 4 | 6.21 | 19.25‡ | (5.25-49.30) | <3 | 28.53‡ | (3.45-103.05) | <3 | 40.65‡ | (4.92-146.86) | 0 | § | (0.00-41.71) |
| Melanoma of the skin | 3 | 2.78 | 4.50 | (0.93-13.15) | <3 | 4.84 | (0.12-26.99) | 0 | § | (0.00-25.44) | <3 | 6.35 | (0.77-22.92) |
| Soft tissue (including heart) | 11 | 8.67 | 14.41‡ | (7.20-25.79) | 7 | 23.86‡ | (9.59-49.16) | 3 | 14.63‡ | (3.02-42.74) | <3 | 3.78 | (0.10-21.06) |
| Female breast | 223 | 2.15 | 4.60‡ | (4.02-5.25) | 160 | 8.60‡ | (7.32-10.05) | 40 | 2.70‡ | (1.93-3.68) | 23 | 1.53 | (0.97-2.29) |
| Cervix | 6 | 2.92 | 7.29‡ | (2.67-15.86) | 4 | 9.36‡ | (2.55-23.96) | <3 | 8.60‡ | (1.04-31.07) | 0 | § | (0.00-22.56) |
| Endometrium | 9 | 4.16 | 5.97‡ | (2.73-11.33) | 6 | 7.80‡ | (2.86-16.98) | <3 | 2.55 | (0.06-14.20) | <3 | 5.78 | (0.70-20.87) |
| Ovary | 72 | 5.66 | 8.68‡ | (6.79-10.94) | 44 | 12.07‡ | (8.77-16.20) | 22 | 10.81‡ | (6.77-16.37) | 6 | 2.30 | (0.84-5.00) |
| Prostate | 8 | 3.62 | 2.95‡ | (1.27-5.80) | 7 | 5.01‡ | (2.01-10.32) | <3 | 1.11 | (0.03-6.17) | 0 | § | (0.00-8.87) |
| Testis | 8 | 1.34 | 6.34‡ | (2.74-12.48) | 4 | 16.01‡ | (4.36-40.99) | 3 | 10.64‡ | (2.19-31.11) | <3 | 1.37 | (0.03-7.62) |
| Urinary bladder | 12 | 0.58 | 1.36 | (0.70-2.37) | 5 | 1.38 | (0.45-3.21) | 4 | 1.57 | (0.43-4.03) | 3 | 1.13 | (0.23-3.30) |
| Brain, central nervous system | 6 | 3.04 | 9.42‡ | (3.46-20.50) | 4 | 11.27‡ | (3.07-28.86) | <3 | 14.00‡ | (1.70-50.59) | 0 | § | (0.00-26.45) |
| Hodgkin lymphoma | 58 | 5.8 | 16.65‡ | (12.64-21.52) | 29 | 24.34‡ | (16.30-34.96) | 22 | 22.84‡ | (14.31-34.58) | 7 | 5.27‡ | (2.12-10.85) |
| Non-Hodgkin lymphoma | 158 | 4.81 | 5.85‡ | (4.97-6.83) | 76 | 6.13‡ | (4.83-7.67) | 59 | 7.44‡ | (5.66-9.59) | 23 | 3.44‡ | (2.18-5.16) |
| Myeloma | 62 | 11.16 | 10.43‡ | (7.99-13.37) | 37 | 8.75‡ | (6.16-12.05) | 22 | 17.18‡ | (10.77-26.01) | 3 | 6.90‡ | (1.42-20.17) |
| First primary malignancy . | . | . | . | . | By latency . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall . | 1.0-4.9 y . | 5.0-9.9 y . | ≥10.0 y . | ||||||||||
| N . | EAR/10 000* . | SIR* . | (95% CI) . | N . | SIR* . | (95% CI) . | N . | SIR* . | (95% CI) . | N . | SIR* . | (95% CI) . | |
| Total† | 801 | 3.04 | 4.70‡ | (4.38-5.04) | 487 | 6.07‡ | (5.54-6.64) | 223 | 4.62‡ | (4.03-5.26) | 91 | 2.17‡ | (1.74-2.66) |
| Buccal cavity, pharynx | 5 | 0.58 | 1.67 | (0.54-3.90) | 4 | 2.37 | (0.64-6.06) | <3 | 1.22 | (0.03-6.77) | 0 | § | (0.00-7.69) |
| Esophagus | 6 | 3.65 | 3.84‡ | (1.41-8.36) | 4 | 3.87‡ | (1.06-9.92) | <3 | 2.66 | (0.07-14.81) | <3 | 6.55 | (0.17-36.52) |
| Stomach | 5 | 1.56 | 2.36 | (0.77-5.50) | 3 | 2.43 | (0.50-7.11) | <3 | 4.33 | (0.52-15.66) | 0 | § | (0.00-8.64) |
| Colon | 25 | 0.2 | 1.16 | (0.75-1.71) | 11 | 1.06 | (0.53-1.89) | 7 | 1.07 | (0.43-2.20) | 7 | 1.50 | (0.60-3.10) |
| Rectum, rectosigmoid junction | 15 | 0.25 | 1.20 | (0.67-1.98) | 7 | 1.11 | (0.45-2.29) | 4 | 1.05 | (0.29-2.68) | 4 | 1.68 | (0.46-4.31) |
| Anus, anal canal, anorectum | 6 | 2.21 | 3.24‡ | (1.19-7.04) | 3 | 3.70 | (0.76-10.80) | <3 | 3.43 | (0.42-12.39) | <3 | 2.18 | (0.06-12.12) |
| Biliary tract | 4 | 4.58 | 5.52‡ | (1.50-14.13) | 3 | 5.77‡ | (1.19-16.86) | <3 | 7.59 | (0.19-42.29) | 0 | § | (0.00-50.48) |
| Larynx | 3 | 2.14 | 3.02 | (0.62-8.81) | 0 | § | (0.00-6.54) | 3 | 10.33‡ | (2.13-30.19) | 0 | § | (0.00-26.26) |
| Lung, bronchus | 65 | 6.49 | 6.82‡ | (5.26-8.69) | 54 | 7.96‡ | (5.98-10.39) | 9 | 4.70‡ | (2.15-8.91) | <3 | 2.38 | (0.29-8.61) |
| Small-cell | 32 | 11.13 | 11.04‡ | (7.55-15.58) | 27 | 14.28‡ | (9.41-20.78) | 3 | 4.51 | (0.93-13.17) | <3 | 5.84 | (0.71-21.09) |
| Non–small-cell | 32 | 4.35 | 4.87‡ | (3.33-6.88) | 26 | 5.37‡ | (3.51-7.87) | 6 | 4.84‡ | (1.78-10.54) | 0 | § | (0.00-7.55) |
| Bones and joints | 4 | 6.21 | 19.25‡ | (5.25-49.30) | <3 | 28.53‡ | (3.45-103.05) | <3 | 40.65‡ | (4.92-146.86) | 0 | § | (0.00-41.71) |
| Melanoma of the skin | 3 | 2.78 | 4.50 | (0.93-13.15) | <3 | 4.84 | (0.12-26.99) | 0 | § | (0.00-25.44) | <3 | 6.35 | (0.77-22.92) |
| Soft tissue (including heart) | 11 | 8.67 | 14.41‡ | (7.20-25.79) | 7 | 23.86‡ | (9.59-49.16) | 3 | 14.63‡ | (3.02-42.74) | <3 | 3.78 | (0.10-21.06) |
| Female breast | 223 | 2.15 | 4.60‡ | (4.02-5.25) | 160 | 8.60‡ | (7.32-10.05) | 40 | 2.70‡ | (1.93-3.68) | 23 | 1.53 | (0.97-2.29) |
| Cervix | 6 | 2.92 | 7.29‡ | (2.67-15.86) | 4 | 9.36‡ | (2.55-23.96) | <3 | 8.60‡ | (1.04-31.07) | 0 | § | (0.00-22.56) |
| Endometrium | 9 | 4.16 | 5.97‡ | (2.73-11.33) | 6 | 7.80‡ | (2.86-16.98) | <3 | 2.55 | (0.06-14.20) | <3 | 5.78 | (0.70-20.87) |
| Ovary | 72 | 5.66 | 8.68‡ | (6.79-10.94) | 44 | 12.07‡ | (8.77-16.20) | 22 | 10.81‡ | (6.77-16.37) | 6 | 2.30 | (0.84-5.00) |
| Prostate | 8 | 3.62 | 2.95‡ | (1.27-5.80) | 7 | 5.01‡ | (2.01-10.32) | <3 | 1.11 | (0.03-6.17) | 0 | § | (0.00-8.87) |
| Testis | 8 | 1.34 | 6.34‡ | (2.74-12.48) | 4 | 16.01‡ | (4.36-40.99) | 3 | 10.64‡ | (2.19-31.11) | <3 | 1.37 | (0.03-7.62) |
| Urinary bladder | 12 | 0.58 | 1.36 | (0.70-2.37) | 5 | 1.38 | (0.45-3.21) | 4 | 1.57 | (0.43-4.03) | 3 | 1.13 | (0.23-3.30) |
| Brain, central nervous system | 6 | 3.04 | 9.42‡ | (3.46-20.50) | 4 | 11.27‡ | (3.07-28.86) | <3 | 14.00‡ | (1.70-50.59) | 0 | § | (0.00-26.45) |
| Hodgkin lymphoma | 58 | 5.8 | 16.65‡ | (12.64-21.52) | 29 | 24.34‡ | (16.30-34.96) | 22 | 22.84‡ | (14.31-34.58) | 7 | 5.27‡ | (2.12-10.85) |
| Non-Hodgkin lymphoma | 158 | 4.81 | 5.85‡ | (4.97-6.83) | 76 | 6.13‡ | (4.83-7.67) | 59 | 7.44‡ | (5.66-9.59) | 23 | 3.44‡ | (2.18-5.16) |
| Myeloma | 62 | 11.16 | 10.43‡ | (7.99-13.37) | 37 | 8.75‡ | (6.16-12.05) | 22 | 17.18‡ | (10.77-26.01) | 3 | 6.90‡ | (1.42-20.17) |